BRIEF-Portola Pharmaceuticals says FDA accepts NDA for priority review for betrixaban

* Portola Pharmaceuticals announces FDA accepts New Drug

Application for priority review and EMA validates marketing

authorization application for oral, Factor Xa inhibitor

anticoagulant betrixaban

Read more